Key result
Guideline-directed medical therapies, including beta-blockers, ACE inhibitors, MRAs, ARNIs, and SGLT2 inhibitors, significantly reduce cardiovascular mortality and heart failure hospitalizations in post-myocardial infarction patients with reduced ejection fraction.
Why the study?
Post-MI patients face an increased risk of heart failure, mortality, and morbidity, prompting a summary of clinical data on established pharmacological therapies.
Do established pharmacological therapies improve outcomes in post-myocardial infarction patients with or without heart failure?
Do established pharmacological therapies improve outcomes in post-myocardial infarction patients with or without heart failure?
Established pharmacological therapies, including neuro-hormonal inhibitors and newer agents like SGLT2 inhibitors, significantly improve outcomes and prevent cardiac remodeling in post-myocardial infarction patients.
Supports GDMT optimization post-MI with reduced EF; confirms prior trial benefits while leaving implementation gaps open.
After myocardial infarction (MI), patients are at a greater risk of heart failure. Post-MI patients with left ventricular systolic dysfunction have a higher risk of mortality or morbidity. Strong and compelling data from randomized trials have demonstrated that drug therapies intended for preventing post-MI remodeling with neuro-hormonal inhibitors can considerably improve short- and long-term outcomes, including death, reinfarction, and worsening heart failure. This article aims at summarizing clinical data on established pharmacological therapies in treating post-MI patients with or without left ventricular systolic dysfunction (LVSD), and with or without signs and symptoms of heart failure.
No takes yet. Share an insight, caveat, or question.
Gautam Swaroop (2022) conducted a review in Post-myocardial Infarction Heart Failure. Pharmacological therapies (beta-blockers, ACEIs, ARBs, MRAs, ARNIs, sGC stimulators, SGLT2 inhibitors) vs. Placebo or standard of care (across various reviewed trials) was evaluated. Guideline-directed medical therapies, including beta-blockers, ACE inhibitors, MRAs, ARNIs, and SGLT2 inhibitors, significantly reduce cardiovascular mortality and heart failure hospitalizations in post-myocardial infarction patients with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: